• Home
        •  | 
        • Partners log-in
      • About Cupron
        • News & Events
        • In the media
        • Cupron Management
        • Regulation
        • FAQ
        • Contact
      • Markets
        • Consumer
        • Industrial
        • Medical
        • Military
      • Cupron Technology
        • The Power of Copper
        • The Cupron Difference
        • Safety Testing
        • The Environment
        • Scientific Data
      • Manufacturing
        • Manufacturing Process
        • Different Substrates
    •  News & Events
    • In the media
    • Cupron Management
    • Regulation
    • FAQ
    • Contact
    • Follow Us

    • Home
    •  › 
    • About Cupron
    •  › 
    • News & Events
    •  › 
    • EPA Supports Claim that Cupron Enhanced EOS Can Kill 99.9% of Bacteria

    EPA Supports Claim that Cupron Enhanced EOS Can Kill 99.9% of Bacteria

    RICHMOND, Va. and NORFOLK, Va. — October 24, 2012 —Cupron, creator of a copper-based antimicrobial technology, and EOS Surfaces, a solid surface manufacturer, jointly announce that their surface, Cupron Enhanced EOS Surfaces, has received the Environmental Protection Agency's (EPA) approval to make a Public Health Claim that their copper-enhanced material can kill greater than 99.9% of Gram negative and Gram positive bacteria* within two hours of exposure. Prior to this, only
    elemental copper and certain copper alloys held this official distinction.

     

    The approval is based on Cupron Enhanced EOS Surfaces' ability to kill specific disease-causing bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa and Escherichia coli (O157:H7). MRSA is one of the most common strains of antibiotic-resistant bacteria and a well-recognized cause of health care-acquired infections (HAIs). The two companies expect this material to help health care organizations and infection control specialists manage HAIs. The product is approved for use in a wide range of applications, including health care.

     

    "The EPA's approval of our public health claims surrounding Cupron Enhanced EOS Surfaces is a pivotal
    moment in not only the commercialization of our technology, but also how health care facilities combat
    hospital infections," said Paul Rocheleau, chairman of Cupron.  "HAIs have a devastating effect on the
    health care environment, causing thousands of deaths and costing billions of dollars each year. While we
    fully acknowledge our surface won't end this problem, we believe these innovative materials will
    provide an additional layer of protection in managing the risks associated with microbial control."


    The Centers for Disease Control and Prevention (CDC) estimates HAIs affect 2 million individuals and
    result in about 100,000 deaths annually. The use of antimicrobial materials for frequently touched
    surfaces may be an effective supplement to existing CDC-prescribed hand-washing and disinfection
    regimens.

     

    In order to submit these claims to the EPA, the surface first had to achieve a 100-percent pass rate of
    thousands of samples at an independent testing laboratory under the highest laboratory standards
    available. The samples were tested in various environmental conditions, cleaning protocols, and for
    efficacy after repeated exposure. EOS Surfaces also performed extensive ASTM testing to support
    mechanical performance claims.

     

    Specifically, the following statements are included in the EPA registration:

    • "This surface continuously reduces bacterial* contamination achieving a 99.9% reduction within
      two hours of exposure."
    • "This surface kills greater than 99.9% of Gram negative and Gram positive bacteria* within two
      hours of exposure."
    •  "This surface kills greater than 99.9% of bacteria* within two hours and continues to kill 99% of
      bacteria* even after repeated contamination."
    • "This surface helps inhibit the buildup and growth of bacteria* within two hours of exposure
      between routine cleaning and sanitizing steps."

     

    *Testing demonstrates effective antibacterial activity against Staphylococcus aureus (ATCC 6538),
    Enterobacter aerogenes (ATCC 13048), Methicillin resistant Staphylococcus aureus (MRSA-ATCC 33592), Escherichia coli O157:H7 (ATCC 35150) and Pseudomonas aeruginosa (ATCC 15442).

     

    "This approval affirms what we've known for a while, that our surface has the potential to make a real
    impact with infection rates among hospitals and other health care institutions," said Ken Trinder, CEO of
    EOS Surfaces. "Our next goal is to establish a network of distributors, fabricators and end-use partners
    to get these materials in the field so that it can begin saving lives, keeping people healthier and reducing
    costs. The EOS Surfaces are designed to be used for countertops, nurses' stations, wall panels and
    building components, showers and lavatory fixtures, furniture and tables, and a broad range of other
    products." 

     

    Cupron and EOS Surfaces will set up a product stewardship program to support the responsible use of
    the technology and obtain feedback from users of the surface. Cupron and EOS, together with various
    health care partners, will further evaluate the benefit of antimicrobial-protected surfaces (hard surfaces
    and textiles) in reducing the amount of disease-causing bacteria in medical facilities.


    Cupron and EOS Surfaces jointly developed this material with a range of performance characteristics
    that provides the mechanical properties of non-porous solid surfaces, the aesthetics for design flexibility
    and high antimicrobial performance. Because the Cupron technology is embedded throughout the
    surface, it will not lose its effectiveness over time and wear-and-tear. In fact, it can be fabricated,
    polished and modified as needed.

     

    Furthermore, EOS is building a new state-of-the-art facility in Norfolk, Virginia for the large-scale
    manufacturing of Cupron Enhanced EOS. The new facility, expected to begin operation in early 2013,
    will have specialized equipment that has been designed to commercialize the proprietary technology for
    a range of products. The new plant will manufacture various thicknesses of Cupron Enhanced EOS cast
    slabs, perform finishing operations, and will have the capability to manufacture pre-made vanities and
    other ancillary surfacing products for microbial control.

     

    Health care organizations, architects, health care design consultants or distributors interested in Cupron<BR>Enhanced EOS Surfaces can contact EOS Surfaces at 800-719-EOS1 or email at kgt@eos-surfaces.com

     

    The use of the Antimicrobial Cupron Enhanced EOS Surface is a supplement to and not a substitute for
    standard infection control practices; users must continue to follow all current infection control
    practices, including those practices related to cleaning and disinfection of environmental surfaces.
    The Antimicrobial Cupron Enhanced EOS Surface has been shown to reduce microbial contamination
    but it does not necessarily prevent cross contamination.

     

    About EOS Surfaces:
    EOS Surfaces, LLC is a solid surface manufacturer, founded in 2005, which revolutionized the solid
    surface industry with the first 3cm surface, a change from most ½" solid surfaces that require additional
    labor costs and edge build up for proper installation. The product received the International Solid
    Surface Fabricators Association's (ISSFA) 2007 Envision Award, honoring the year's most innovative
    product.

     

    EOS Surfaces also offers GEOS, an environmentally friendly option that uses recycled glass in its
    construction, and Cupron Enhanced EOS, the industry's first EPA registered, copper-infused hard surface
    that is approved to make Public Health Claims regarding its antimicrobial capabilities. For more
    information, visit www.eos-surfaces.com.

    •  
      • © Copyright Cupron 2008, All rights reserved.
        • Cupron
        •   |  
        • About Cupron
        •   |  
        • Markets
        •   |  
        • The Power of Copper
        •   |  
        • FAQ
        •   |  
        • Cupron Technology
        •   |  
        • Manufacturing

      • Product claims that can be made for products containing Cupron technology vary by country and by product. In particular, all antimicrobial claims in the US
        are strictly regulated by the US EPA, which allows only preservative "treated article" claims, while structure-function/disease-treatment claims in the US need
        to be pre-market approved by the US FDA. Partners and customers should consult Cupron for all questions regarding product claims in particular countries

    •